|
MechanismCYP51A1 inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date19 Mar 2002 |
100 Clinical Results associated with Hikma Farmacêutica (Portugal) SA
0 Patents (Medical) associated with Hikma Farmacêutica (Portugal) SA
100 Deals associated with Hikma Farmacêutica (Portugal) SA
100 Translational Medicine associated with Hikma Farmacêutica (Portugal) SA